Skip to content

Clinical Evaluation of the Antibacterial Activity of Thioglycosides Extracted from White Mustard - Bamberka in Oral Hygiene. Evaluation of Periodontal Parameters and Oral Microbiota in Patients.

Clinical Evaluation of the Antibacterial Activity of Thioglycosides Extracted from White Mustard - Bamberka in Oral Hygiene.

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06908265
Enrollment
113
Registered
2025-04-03
Start date
2015-03-31
Completion date
2017-01-31
Last updated
2025-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caries, Dental, Gingival and Periodontal Disease

Keywords

Caries., thioglycosides, periodontitis, gingivitis, lactobacillus, toothpaste, mustard

Brief summary

Brief Summary The goal of this randomized clinical trial is to evaluate the clinical and antibacterial effects of a herbal toothpaste containing white mustard (Sinapis alba) extract in patients diagnosed with gingivitis. The main questions it aims to answer are: Does the herbal toothpaste significantly reduce plaque index (PI), approximal plaque index (API), gingival index (GI), and bleeding on probing (BoP) compared to a placebo toothpaste? Does the herbal toothpaste effectively reduce the bacterial loads of Streptococcus mutans and Lactobacillus spp. in saliva compared to a placebo? Researchers will compare the effects of the herbal toothpaste to a placebo toothpaste to determine its efficacy in improving periodontal parameters and reducing bacterial levels. Participants will: Be randomly assigned to one of two groups: test group (herbal toothpaste) or control group (placebo toothpaste). Use the assigned toothpaste twice daily for 4 weeks. Undergo clinical evaluations at baseline (T0) and after 4 weeks (T1), including measurements of PI, API, GI, and BoP. Provide saliva samples at T0 and T1 for microbiological analysis of Streptococcus mutans and Lactobacillus spp. bacterial loads.

Interventions

DRUGToothpaste including mustard extract

Intervention: Herbal toothpaste containing 0.5% white mustard (Sinapis alba) extract. To assess its effect on plaque index (PI), approximal plaque index (API), gingival index (GI), bleeding on probing (BoP), and bacterial loads of Streptococcus mutans and Lactobacillus spp. Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the assigned toothpaste.

DRUGPlacebo

lacebo toothpaste, formulated identically to the experimental toothpaste but without white mustard extract. Serves as a control to compare the antibacterial and clinical effects of the herbal toothpaste. Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the placebo toothpaste.

Sponsors

Medical University of Warsaw
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Masking description

Participants were randomly assigned to two groups and blinded - Experimental vs placebo. They got toothpaste samples in identically marked white tubes.

Intervention model description

Participants were divided into two groups, experimental and control. The experimental group received an intervention - mustard toothpaste. The control group received a control toothpaste without mustard extract.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* age between 18 and 65 years, * the presence of at least 20 teeth excluding third molars, * a diagnosis of gingivitis according to the 2017 World Workshop * non-smokers. * the motivation to take part in the study, * proper oral home hygiene * sign a consent agreement for the participation in the study

Exclusion criteria

* patients aged \<18 * the presence of less than 20 teeth * severe systemic diseases and diseases that require regular systemic drugs (diabetes mellitus) * the use of systemic antibiotics during the last 3 months or local antiseptics that may affect biofilm formation (antibacterial mouth rinses containing chlorhexidine 4 weeks or less prior recruitment) * allergy to mustard or any other compound of experimental toothpaste * patients undergoing orthodontic treatment * women who were pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Change in Plaque Index (PI) from Baseline (T0) to Week 4 (T1)From start of intervention, 4 weeks to end of intervention and data collection.Change in Plaque Index (PI) from Baseline (T0) to Week 4 (T1) Measured using the Silness and Loe Plaque Index (PI) Scale to assess plaque accumulation on tooth surfaces. Unit: Plaque score (0-3 scale). Time Frame: Baseline (T0) and Week 4 (T1).
Change in Bleeding on Probing (BoP) from Baseline (T0) to Week 4 (T1)From start of intervention, 4 weeks to end of intervention and data collection.Change in Bleeding on Probing (BoP) from Baseline (T0) to Week 4 (T1) Measured using the Ainamo and Bay method, which evaluates gingival bleeding after gentle probing. Unit: Percentage of bleeding sites. Time Frame: Baseline (T0) and Week 4 (T1).

Secondary

MeasureTime frameDescription
Change in Approximal Plaque Index (API) from Baseline (T0) to Week 4 (T1)4 weeksMeasured based on the presence of plaque in interdental areas. Unit: Percentage of interdental sites with plaque. Time Frame: Baseline (T0) and Week 4 (T1).
Change in Gingival Index (GI) from Baseline (T0) to Week 4 (T1)4 weeksMeasured using the Loe and Silness Gingival Index (GI) Scale to assess the degree of gingival inflammation. Unit: Gingival index score (0-3 scale). Time Frame: Baseline (T0) and Week 4 (T1).
Change in Salivary Bacterial Loads of Streptococcus mutans and Lactobacillus spp. from Baseline (T0) to Week 4 (T1)4 weeksMeasured using the Caries Risk Test (CRT, Ivoclar Vivadent) to determine bacterial colony counts in saliva samples. Unit: Colony-forming units per milliliter (CFU/ml). Time Frame: Baseline (T0) and Week 4 (T1).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026